home / stock / rvph / rvph quote
Last: | $3.20 |
---|---|
Change Percent: | -1.57% |
Open: | $3.23 |
Close: | $3.20 |
High: | $3.2875 |
Low: | $3.1 |
Volume: | 109,318 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.2 | $3.23 | $3.2 | $3.2875 | $3.1 | 109,318 | 05-03-2024 |
$3.18 | $3.29 | $3.18 | $3.3 | $3.14 | 89,189 | 05-02-2024 |
$3.26 | $3.09 | $3.26 | $3.29 | $3.06 | 78,760 | 05-01-2024 |
$3.06 | $2.91 | $3.06 | $3.15 | $2.9 | 112,981 | 04-30-2024 |
$2.9 | $3 | $2.9 | $3.07 | $2.9 | 114,659 | 04-29-2024 |
$2.99 | $2.97 | $2.99 | $3.08 | $2.94 | 116,230 | 04-26-2024 |
$2.98 | $3.01 | $2.98 | $3.1 | $2.9 | 107,227 | 04-25-2024 |
$3.02 | $3.01 | $3.02 | $3.13 | $2.9 | 77,687 | 04-24-2024 |
$3.06 | $3.15 | $3.06 | $3.19 | $3.01 | 77,792 | 04-23-2024 |
$3.09 | $3.05 | $3.09 | $3.15 | $2.95 | 111,561 | 04-22-2024 |
$3.02 | $3 | $3.02 | $3.08 | $2.95 | 139,500 | 04-19-2024 |
$3.02 | $3.2 | $3.02 | $3.2 | $2.98 | 126,072 | 04-18-2024 |
$3.2 | $3.3 | $3.2 | $3.3607 | $3.17 | 98,296 | 04-17-2024 |
$3.33 | $3.34 | $3.33 | $3.42 | $3.27 | 93,509 | 04-16-2024 |
$3.48 | $3.43 | $3.48 | $3.6 | $3 | 735,387 | 04-15-2024 |
$3.69 | $3.72 | $3.69 | $3.81 | $3.66 | 93,949 | 04-12-2024 |
$3.79 | $3.69 | $3.79 | $3.8 | $3.62 | 180,619 | 04-11-2024 |
$3.68 | $3.56 | $3.68 | $3.68 | $3.5 | 65,659 | 04-10-2024 |
$3.64 | $3.63 | $3.64 | $3.68 | $3.49 | 127,717 | 04-09-2024 |
$3.63 | $3.56 | $3.63 | $3.64 | $3.44 | 86,012 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigat...
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-labe...
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024;...